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Summary and Key Points 
Prevention 
1. Currently in the United States, tobacco use is the single greatest 
preventable cause of cancer. Physicians should strongly 
encourage patients to quit smoking or chewing tobacco or, even 
better, to never take up these habits. 
2. Some viral and bacterial infections can cause cancer. It is hoped 
that vaccines against specific infectious agents (e.g., Hepatitis B, 
human papilloma virus) will result in reductions in cancers 
associated with these infections. 
3. Obesity is associated with an increased risk of a number of 
malignancies. While it makes sense to urge patients to adopt 
“healthy lifestyles” with attention to sensible diets and moderate 
exercise, no study has shown any particular diet or nutritional 
supplement capable of lowering the risk of developing cancer. 
4. Some cancers can be prevented by taking drugs that block 
carcinogenic pathways (chemoprevention). In individuals at high 
risk of developing certain cancers, prophylactic removal of the 
organ at risk (e.g., mastectomy, oophorectomy, and colectomy) 
can prevent subsequent cancer. 
Screening 
1. The goal of cancer screening tests is to lower the morbidity and 
mortality from cancer by discovering cancers at an early, treatable 
stage. 
2. Effective cancer screening currently exists for breast, cervical, and 
colorectal cancers. 
  
Introduction 
Current treatments of cancer are imperfect and entail risks. For many 
malignancies, the best “treatment” is to prevent the cancer from ever 
appearing in the first place. Cancer prevention refers to interventions that 
reduce the incidence of cancer. Such interventions can include reduction 
of exposure to known carcinogens (e.g., tobacco), treatment with drugs 
that lower cancer risk (chemoprevention), vaccination against infectious 
agents that cause cancer, surgery to remove organs at high risk of 
developing cancer in individuals with familial cancer syndromes, or the 
adoption of a “healthy lifestyle” that modifies cancer risk. Cancer 
screening shares some concepts with cancer prevention. A screening 
test like colonoscopy that results in the removal of polyps that have the 
potential of progressing to cancer can be a form of cancer prevention. 
Cancer screening is also utilized to find an established cancer at an 
early, treatable stage. 
Cancer screening tests are employed in healthy, asymptomatic patients 
so it is imperative that these tests are safe and effective. A “positive” 
screening test will invariably lead to additional, increasingly invasive 
tests. It is not good enough to find a cancer early in its growth if no 
effective treatment exists for it or if the cancer was never going to grow 
and harm the patient during the course of the patient’s life. An effective 
screening test should not just find a cancer early; it should lead to a 
reduction in morbidity and mortality from the malignancy. 
This chapter will provide a brief review of cancer prevention and 
screening. It should be noted that preventive care literature frequently 
refers to “primary”, “secondary”, and “tertiary” prevention measures. The 
U.S. Preventive Services Task Force defines primary prevention as 
measures designed to prevent the occurrence of a disease; the 
discussion of cancer prevention in this section will be restricted to 
primary prevention. Secondary prevention includes anything that detects 
disease at a stage before it becomes clinically apparent when 
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interventions might be more effective – this definition typically applies to 
cancer screening. Tertiary prevention includes the care of active disease 
and will not be covered in this chapter. Interested students can acquire 
additional information through the National Cancer Institute, the 
American Cancer Society, or the Centers for Disease Control and 
Prevention web sites. 
Cancer Prevention 
Smoking Cessation 
It is impossible to exaggerate the impact of tobacco use on cancer 
incidence and mortality.1 Tobacco consumption by men in the United 
States began to skyrocket after the introduction of industrial production of 
cigarettes in the early 20th Century. In the 1960’s, over 50% of men in the 
United States were smoking. Women took up the smoking habit during 
and after World War II, and over one-quarter of women in the United 
States were smoking by the 1980’s. The incidence of lung cancer, a 
once rare disease, began to rise about 20-30 years after the increase in 
tobacco consumption. Today, thanks to decades of anti-smoking 
awareness, smoking rates among both sexes in the United States are 
now down to about 20%. Lung cancer incidence and mortality in men 
have fallen by over 20% since reaching peak levels in 1990. 
Although lung cancer is the leading cause of tobacco-induced cancer 
mortality, smoking increases the risk of a variety of other disorders. 
Table 1 lists the variety of cancers which are linked to smoking. Some 
cancers (e.g., larynx, esophagus), like lung cancer, occur because of 
direct exposure to the carcinogens in cigarette smoke. Others (e.g., 
renal, bladder) are due to exposure of carcinogens that are absorbed 
from cigarette smoke and concentrated in excretory organs. Besides 
cancer, cigarette smoking markedly increases morbidity and mortality 
from other diseases, including stroke, heart disease, peripheral vascular 
disease, and chronic lung disease. 
Table 1. Cancers Strongly Associated With Tobacco Use 
Lung Cancer 
Esophageal Cancer 
Kidney Cancer 
Bladder Cancer 
Cancers of the Head & Neck (Tobacco Smoking & Chewing) 
Smoking cessation lowers the risk of smoking related cancers and other 
diseases. Smoking cessation is, therefore, the single most effective 
measure that can be taken in any smoking patient to lower the risk of 
premature death. Because of the addictive potency of nicotine, smoking 
cessation can be very difficult. A variety of techniques (Table 2), 
including pharmacological intervention, have been shown to have some 
effectiveness in helping smokers quit. Importantly, the simple acts of a 
physician asking a patient about their desire to quit and encouraging the 
patient to try to quit can increase the probability that a patient will 
successfully stop smoking. 
Table 2. Strategies to Aid Smoking Cessation 
Pharmacological 
Nicotine Replacement – Transdermal Patch, Gum, Lozenge, Inhaler 
Nasal Spray 
Nicotinic Acetylcholine Receptor Binding – Varenicline 
Antidepressant - Bupropion 
Behavioral 
Hypnosis 
Support Groups/Counseling 
Infections and Cancer 
A number of infectious agents can cause cancer. Some strains of human 
papilloma virus are associated with cancers of the cervix, anus, penis, 
and oropharynx. Hepatitis B and C infections can cause hepatocellular 
carcinoma. Epstein-Barr virus is associated with the epidemic form of 
Burkitt’s lymphoma and Helicobacter pylori infection contributes to 
gastric cancer. It is hoped that vaccines may reduce the risk of cancer 
from some infections. A vaccine against oncogenic strains of human 
papilloma virus has been shown to reduce the incidence of precancerous 
cervical lesions. Similarly, effective use of the vaccine against hepatitis B 
may result in a reduction in the incidence of hepatocellular carcinoma. 
Obesity and Healthy Lifestyles 
The rising incidence of obesity in industrialized countries over the last 
quarter-century has been recognized as a major public health problem. 
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In addition to contributing to increased rates of diabetes, heart disease, 
and joint disease, obesity is associated with an increased risk of a variety 
of malignancies.2 Cancers of the breast, colon, esophagus, uterus, and 
kidney all appear at increased frequency in obese individuals. 
Additionally, obese women with a history of early stage breast cancer 
appear to have an increased risk of relapse of their disease compared to 
women of ideal body weight with breast cancers of similar stage. The 
exact reasons for the higher cancer risks resulting from obesity are not 
clear. However, a number of hormones and growth factors are elevated 
in obese individuals, including estrogen, insulin, insulin-like growth factor, 
and leptin and these may help promote cancer cell growth. 
There are probably many factors that have contributed to the increasing 
incidence of obesity. These include the availability of cheap, high calorie 
foods. Additionally, labor-saving devices and sedentary jobs and habits 
result in decreased caloric expenditure. Unlike vaccines that prevent 
infections, there is unlikely to be a “magic pill” that will safely curb 
obesity. Rather, patients should be encouraged to adopt life-long 
“healthy lifestyles” that include both sensible dietary habits combined 
with regular moderate exercise. 
It is impossible to point to any one diet as the “perfect” diet.3 However; it 
appears that a well-balanced diet, rich in fresh fruits and vegetables, is a 
good starting point. Dietary recall studies have demonstrated that 
individuals who take in large amounts of fresh fruits and vegetables have 
a lower risk of some cancers than those who take low amounts of such 
foods. By contrast, no large randomized trial of dietary supplements, 
including vitamins, has shown a reduction in the risk of developing 
cancer (Table 3). One explanation for this apparent paradox may be that 
it is more beneficial to obtain a variety of nutrients from whole foods than 
individual purified nutrients from pills. 
 
 
 
 
 
 
 
 
 
Table 3. Dietary Supplement Trials and Cancer Risk 
Dietary 
Supplement Cancer Effect Study Reference 
Multi Vitamin 
(MV) 
Cancer in 
women No effect 
Observational 
(WHI) 
Neuhouser et 
al., Arch Int 
Med, Feb. 
2009 
Selenium 
(Se) Prostate No effect 
Prospective 
intervention 
(SELECT) 
Lippman, et 
al., JAMA, 
Jan. 2009 
Vitamin C 
All cancer in 
men No effect
Prospective 
intervention  
(Physicians’ 
Health Study II)
Gaziano et al., 
JAMA, Jan. 
2009
Vitamin E 
Prostate, all 
cancer in men No effect
Prospective 
intervention, 
two trials 
(SELECT and 
Physicians’ 
Health Study II)
Lippman et al.  
Gaziano et al.,  
JAMA, Jan. 
2009
Calcium + 
Vitamin D
Breast cancer 
in women No effect
Prospective 
observational 
(WHI)
Chlebowski et 
al., JNCI, Nov. 
2008 
Folate Prostate More incidence
Prospective 
intervention 
(Aspirin/Folate 
Polyp 
Prevention 
Study)
Figueiredo et 
al., JNCI, 
March 2009 
Se + Vit E + 
βcarotene Gastric Less death
Prospective 
intervention 
(Linxian 
Nutrition 
Intervention 
Trial)
Qiao et al., 
JNCI, April 
2009
 
Chemoprevention 
Chemoprevention refers to the use of pharmacologic agents to prevent 
cancer. At present, the only drugs shown to prevent the development of 
cancer block the formation of tumors dependent on hormones for their 
growth. Tamoxifen and raloxifene are approved for breast cancer 
prevention. They are selective estrogen receptor modulators (SERM) 
that prevent carcinogenesis in breast cells by binding to the estrogen 
receptor in those cells. Finasteride is a 5-α reductase inhibitor that blocks 
the conversion of testosterone to dihydrotesterone (DHT). Reduction of 
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DHT prevents progression of prostate cells to cancer cells. While the 
American Society of Clinical Oncology (ASCO) and the American 
Urological Association (AUA) have issued guidelines that support the use 
of finasteride for prostate cancer prevention, finasteride has not yet 
received FDA approval for that indication. 
It is important to appreciate that when tamoxifen, raloxifene, and 
finasteride are given to patients for cancer prevention, it is healthy 
people who do not have a disease who are being exposed to the drugs. 
Accordingly, side effects of any chemopreventive drug should be 
minimal. Tamoxifen and raloxifene can cause hot flashes and deep vein 
thromboses and tamoxifen can increase the risk of endometrial cancer. 
Finasteride can cause gynecomastia, impotence, and reduced libido. 
Any patient and physician considering using these drugs for 
chemoprevention has to weigh the potential benefit of cancer risk 
reduction against the risk of side effects of the drugs.4 
Surgery and Cancer Prevention 
A number of inherited genetic mutations have been identified that 
markedly increase the risk of developing certain cancers. Some of these 
cancers occur in organs that can be removed with no impact on life span. 
For example, women who inherit mutations in BRCA1 or BRCA2 have an 
elevated risk of developing breast and ovarian cancers. These women 
can be offered bilateral mastectomy and oophorectomy and those 
operations will markedly lower the risk of developing breast or ovarian 
cancer. Similarly, familial adenomatous polyposis coli syndrome is due to 
an inherited mutation in the APC gene and typically results in the 
development of colon cancer before the age of 40. Individuals with this 
syndrome are routinely offered total colectomy at a young age. 
Just as the risks and benefits of chemoprevention need to be carefully 
considered for each individual patient, it is important to consider the 
implications of the surgical removal of an organ to prevent the 
subsequent development of cancer. Besides the immediate surgical risks 
(e.g., infection, bleeding), there may be long-term physical and 
psychological risks associated with prophylactic surgery. It is vital that 
patients be thoroughly counseled about the short and long-term risks 
before embarking on such surgery. 
Cancer Screening 
The primary goal of cancer screening is to improve survival from a 
cancer by finding the cancer at an early stage when it is more likely to be 
cured. Because large numbers of healthy people may undergo cancer 
screening, it is important that screening be affordable and safe.5 In the 
United States, there is wide acceptance of screening for three cancers – 
breast, colorectal, and uterine cervix. More controversial is the value of 
current screening for prostate cancer and lung cancer. 
No test is perfect. Statistical terms that mathematically assess tests 
include sensitivity and specificity. In the case of cancer screening, 
sensitivity refers to the ability of a test to find a cancer in those 
individuals who are afflicted with the disease and specificity is the 
measure of how well a test correctly identifies those individuals who do 
not have cancer (Figure 1). To be effective, a screening test should not 
only be sensitive (able to find cancer), but should also be very specific 
(able to identify healthy persons). The following example provides some 
idea of the need for high specificity. About 20% - roughly 40 million 
people - of the adult population smokes and there will be about 200,000 
cases of lung cancer diagnosed this year in the United States. If a 
screening test for lung cancer has sensitivity and specificity both of 99% 
and all 40 million smokers are screened, then the screening test will miss 
about 2000 cases of cancer (99% sensitivity means 1% of cancers are 
missed – this result is called a false-negative). However, it will incorrectly 
identify almost 400,000 healthy people as having lung cancer (99% 
specificity means 1% of healthy people are mislabeled – this result is 
called a false-positive). Those 400,000 people without lung cancer may 
undergo further tests, including lung biopsies that can be costly, invasive, 
and risky. Thus, even a test with 99% sensitivity and specificity can result 
in twice as many people being given an incorrect diagnosis that they 
have cancer than are correctly diagnosed with cancer1. 
This example also highlights another aspect of screening, which is that 
the incidence of the screened condition will also affect the outcome of 
screening tests. For example, if lung cancer was a rare disorder with only 
10,000 cases annually, a screening test with 99% sensitivity and 
specificity, if applied to 40 million people, will still incorrectly identify 
about 400,000 people as having lung cancer, so the ratio of false-
positive results to true-positive results will now be 40:1 – forty people will 
be incorrectly identified as having lung cancer for every patient correctly 
diagnosed with the disease! This exercise illustrates the importance of 
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screening tests being highly specific, particularly when they are 
employed to find uncommon diseases. The mathematical concept that 
explores the effect of disease incidence on screening test outcome in 
detail is known as Baye’s Theorum. 
Breast Cancer Screening 
Breast cancer is, in many ways, an ideal malignancy to screen for. It is 
the most common non-skin cancer diagnosed in women in the United 
States. Most breast cancers grow at rates that permit detection by 
mammography before they become symptomatic. Mammography trials 
date back almost half a century to the HIP trial from the 1960’s. At this 
point, trials in North America and Europe have enrolled over 500,000 
women randomly assigned to mammographic screening or no screening 
for breast cancer. Taken together, these studies have shown that 
mammography lowers the risk of dying of breast cancer by at least 15%. 
That mammography lowers the risk of dying from breast cancer is not 
controversial. However, many issues regarding mammography continue 
to be subjects of debate and research. Mammography has been 
extensively studied in women between the ages of 50 and 70 and is 
strongly recommended for them. Very few women over the age of 70 
have been included in randomized trials of screening so it is not known 
what benefit elderly women may realize from screening. There are also 
differences of opinion over the age at which women should begin 
screening. Because breast cancer is less common in younger women, 
there is concern over the increased number of false-positive 
mammograms relative to true-positive studies in younger age groups. It 
is also not clear what the optimal interval should be between 
mammograms. Randomized trials have had women undergo 
mammograms at intervals ranging between 12 and 33 months and it is 
not obvious that more frequent intervals provide enhanced benefit 
compared to longer intervals. Finally, the technology used for breast 
cancer screening has changed over the last fifty years. Breast MRI, 
widely used in the evaluation of women with an established diagnosis of 
breast cancer, is now recommended for screening women at very high 
risk of developing breast cancer (e.g., women harboring mutations in 
BRCA1 or BRCA2). Whether breast MRI, or any other technology, will 
replace mammography for screening the general population will depend 
on the results of well done trials comparing the different techniques. 
Currently, the most commonly accepted standard in the United States is 
to recommend to women that they begin annual mammography 
sometime between the age of 40 and 50 and continue to at least the age 
of 75. Older women in good health could consider continuing annual or 
biannual mammogram screening past the age of 70. 
Cervical Cancer Screening 
Cervical cancer is almost entirely due to infection by oncogenic strains of 
the human papillomavirus (HPV). The virus is sexually transmitted, so 
screening for cervical cancer should begin after a woman becomes 
sexually active. The current screening test is the Papanicolaou smear 
(Pap test) in which cells scraped from the cervix are viewed for evidence 
of dysplasia. The Pap test has a significant incidence of false-positive 
results due to inflammation. There has never been a randomized trial of 
cervical cancer screening to clearly define the extent of benefit from the 
test. However, since the introduction of the Pap smear over fifty years 
ago, the death rate due to cervical cancer in the United States has fallen 
by over 70% and continues to decline at the rate of about 4% per year. In 
2012 the United States Public Health Service Task Force on Prevention 
issued new guidelines for cervical cancer screening which have been 
endorsed by the American College of Obstetricians and Gynecologists 
(ACOG). Women should begin screening at the age of 21 and should 
have Pap smears every other year until age 30. At that point, screening 
should occur every three years. Screening can be discontinued for 
women at the age of 65 to 70 if they have had three consecutive normal 
Pap smears and are in a monogamous sexual relationship. These new 
guidelines replaced earlier standards that called for earlier and more 
frequent screening. The current guidelines recognize that cervical cancer 
may take years to develop and therefore the net benefit of screening 
young women shortly after they become sexually active or screening all 
women annually will be minimal. Although it is hoped that widespread 
use of HPV vaccination will reduce the incidence of cervical cancer, at 
present ACOG recommends that women who have received a HPV 
vaccine follow the screening guidelines noted above. 
Colorectal Cancer Screening 
Colorectal cancers arise from colonic epithelial cells as the result of 
mutations in oncogenes and tumor suppressor genes. As these cells 
accumulate genetic changes, they may gradually progress from 
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phenotypically normal cells to adenomatous cells to cancer cells. If these 
abnormal cells can be detected and removed in the adenomatous (polyp) 
state, then progression to cancer should be stopped. The tests most 
commonly used in the United States for colorectal cancer screening are 
fecal occult blood testing (FOBT) and colonoscopy. FOBT has been 
studied in five randomized trials in the United States and Europe and has 
demonstrated a 15-33% reduction in the risk of dying from colorectal 
cancer in the screened groups. 
Screening colonoscopy has never been evaluated in a randomized trial. 
Cohort studies suggest that screening colonoscopy can also lower the 
risk of dying from colon cancer. In this regard, note that most patients in 
FOBT programs would undergo colonoscopy if they were actually found 
to have a positive FOBT. At present, both the American Cancer Society 
and the United States Preventive Services Task Force recommend that 
adults begin screening for colorectal cancer at the age of 50. Acceptable 
methods of screening include colonoscopy every ten years or annual 
FOBT. 
While screening colonoscopy is routinely pursued in the United States in 
spite of the lack of data from randomized trials, a trial has now been 
published that supports the use of flexible sigmoidoscopy for colon 
cancer screening. In the United Kingdom over 170,000 patients between 
the ages of 55 and 64 were randomly assigned to one flexible 
sigmoidoscopy or no screening. The screened group realized a 23% 
reduction in colon cancer incidence and a 31% reduction in death due to 
colon cancer after a median follow-up of over 11 years. 
Lung Cancer 
Lung cancers are often very aggressive cancers that kill most people 
who are diagnosed with the malignancy. Stage IV (metastatic) lung 
cancer has a median survival of less than a year. Unlike many cancers 
that can affect almost any human, lung cancers are found with greatest 
frequency in smokers. Thus, it makes sense that a screening program 
restricted to smokers that was able to find lung cancers at an early stage 
would be an effective way to lower mortality from lung cancer. 
Unfortunately, until recently, no lung cancer screening program has 
demonstrated a reduction in lung cancer mortality. 
In the 1970’s and 1980’s studies using either screening chest x-rays, 
induced sputum cytology, or both tests had remarkably similar findings. 
All trials showed that screening resulted in the discovery of more early 
stage lung cancers than were found in smokers who did not undergo 
screening. Importantly, screening permitted the surgical resection of 
many more early stage (stage I and II) tumors. Despite these findings, 
individuals randomized to screening had no reduction in risk of death due 
to lung cancer. 
Recently, low dose computerized tomography (CT) of the chest has been 
advocated as a potentially useful screening technique for lung cancer. 
Like earlier trials of lung cancer screening, chest CT is able to find many 
early stage cancers before such cancers would come to medical 
attention by causing symptoms. In November, 2010, the National Cancer 
Institute (NCI) released initial results from the National Lung Screening 
Trial, and the study was eventually published in August, 2011.6 This trial 
randomized 53,000 smokers between the ages of 55 and 74 to screening 
with annual chest CT for three years or standard chest x-ray. Data from 
the trial showed that patients who underwent screening chest CTs had a 
20% reduction in lung cancer mortality compared to those patients who 
only had screening chest x-rays. Published results of the trial have 
shown that it is necessary to screen 320 patients annually for three years 
to benefit one patient. A full economic analysis of this screening 
approach been published and shows a wide range in the potential cost of 
lung cancer screening.. A number of national organizations (American 
Cancer Society, American College of Chest Physicians, National 
Comprehensive Cancer Network) now recommend that physicians 
consider low dose chest CT screening for some patients who smoke or 
have a history of smoking. In July 2013, the US Preventive Services 
Task Force recommended low dose CT screening annually for adults 
age 55-79 with a 30-pack year smoking history or who have quit in the 
last 15 years.7 
Controversies in Cancer Screening 
As previously discussed, the principle goal of cancer screening tests is to 
reduce the mortality from a screened cancer. Simply being able to find 
cancers at an early stage is not enough to justify a screening test if such 
a discovery does not result in a decrease in mortality (or morbidity) from 
the cancer. However, it can be difficult for the public – and physicians – 
to accept the notion that finding cancer at an early stage may not be 
beneficial to patients. The current status of screening for prostate cancer 
can help illustrate this conundrum. 
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Prostate specific antigen (PSA) is a protease secreted by normal and 
malignant prostate cells. It is easy to measure with a simple blood test. 
PSA levels typically rise as men age, reflecting the hypertrophy of the 
prostate that accompanies aging. However, PSA levels above a certain 
range are increasingly likely to indicate the presence of prostate cancer. 
Checking a man’s PSA on a regular basis has been advocated by some 
as a way to find prostate cancer at an early, treatable stage. Indeed, 
trials that date back two decades have consistently shown that PSA 
screening can help to find early stage prostate cancer. The widespread 
use of PSA screening in the United States led to a dramatic increase in 
the incidence of prostate cancer diagnosis – rising from about 100 new 
cases per 100,000 men in the late 1970’s to about 230 new cases per 
100,000 men in the early 1990’s. 
While PSA screening unquestionably led to the sharp change in the 
number and stage of newly diagnosed prostate cancer cases, it has 
been very difficult to show that screening also led to an improvement in 
survival from prostate cancer. One reason for this is that prostate cancer 
is frequently a slowly growing tumor that may never cause problems for a 
man during his lifetime. Consequently, diagnosing prostate cancer at an 
early stage may merely expose a man to the risks of treatment (surgery 
or radiation) without affecting his overall life span. 
Two large studies, one from the United States and one from Europe, 
looked at the impact of PSA screening on prostate cancer outcomes and 
were published recently. Though screened groups in both trials had a 
higher incidence of prostate cancer diagnosed, the US trial showed no 
impact of screening on mortality from prostate cancer. The European trial 
showed a modest improvement in prostate cancer mortality from 
screening, but concluded that almost 50 screened men would have to be 
treated for prostate cancer to save one life. The results from these trials 
have not settled the controversy over the usefulness of screening for 
prostate cancer. Passionate advocates on both sides of the issue have 
seized on the recent data to support their positions. At present, no major 
national body recommends routine prostate cancer screening with PSA 
testing. The United States Preventive Services Task Force recommends 
against prostate cancer screening. Some other groups recommend that 
physicians thoroughly counsel men about the limitations and risks of 
screening before embarking on a screening program. 
 
Conclusion 
Prevention of cancer is surely the most cost-effective way to lower 
mortality from cancer. Cessation of tobacco use and adoption of a 
healthy lifestyle are sensible steps that will provide a number of benefits 
to patients. Vaccines that reduce the risk of infection by oncogenic 
viruses are also expected to lower the risk of specific cancers. Drug 
treatment (chemoprevention) and prophylactic surgery can lower the risk 
of certain cancers in selected populations. 
Screening for a cancer should be adopted if the screen lowers the 
mortality of the cancer. Some screening techniques can do this for 
selected cancers and national organizations recommend screening for 
breast, cervix, lung, and colorectal cancers in appropriate populations. 
However, controversies still exist about some of these screening 
programs. 
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Thought Questions 
1. A researcher claims to have a blood test that reliably identifies 
patients with cancer of the pancreas. She argues passionately that 
this should become a standard test in order to diagnose this usually 
fatal malignancy at an early stage. What additional information is 
needed before deciding if such a test is a useful screening test? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
 
2. The claim has been made that sharks never get cancer and, 
therefore, shark cartilage can prevent cancer. You wish to test that 
hypothesis. What populations should you treat with shark cartilage 
and why? What limitations to drug procurement can you imagine 
(besides the obvious teeth problem). 
Your answer: 
 
 
 
 
 
 
 
 
 
Expert Answer 
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Glossary 
Adenomatous cells (Polyp)– A benign growth resulting from the 
acquisition of genetic alterations that lead to hyperplasia. Additional 
mutations may lead to the development of cancer. 
APC gene- A tumor suppressor gene located on chromosome 5. 
Baye’s Theorem- A statistical theorem that states that the probability that 
a positive test is true is based in part on the frequency of the condition 
that the test is searching for. 
Bilateral mastectomy- Surgical removal of both breasts. 
Bilateral oophorectomy- Surgical removal of both ovaries. 
BRCA1- A tumor suppressor gene located on chromosome 17. 
BRCA2- A tumor suppressor gene located on chromosome 13. 
Cancer prevention- Interventions that reduce the incidence of cancer 
Cancer screening- Tests to find cancer early; reducing the morbidity and 
mortality from the malignancy 
Chemoprevention- Treatment with drugs that lower cancer risk 
Colonoscopy- Direct fiber-optic examination of entire colon 
False-negative- A test result that incorrectly states that the condition 
being tested for does not exist in the subject undergoing the test. 
Obesity- Accumulation of excess body fat to the extent that the health of 
an individual may be adversely affected. 
Oncogenes- A mutated gene that can cause cancer. 
Phenotypically normal cells- Cells that exhibit normal behavior.  
Primary prevention- Measures designed to prevent the occurrence of a 
disease 
Randomized trial- A trial in which subjects are allocated by chance to 
one intervention or another. 
Secondary prevention- Anything that detects disease at a stage before it 
becomes clinically apparent when interventions might be more effective 
(cancer screening) 
Sensitivity- In the case of cancer screening, refers to the ability of a test 
to find a cancer in those individuals who are afflicted with the disease 
Sigmoidoscopy- Examination of anus, rectum and sigmoid colon 
Specificity- In the case of cancer screening, the measure of how well a 
test correctly identifies those individuals who do not have cancer  
Tertiary prevention- Care of active disease 
Total colectomy- Surgical removal of the entire colon. 
Tumor suppressor genes- A gene whose loss of function predisposes a 
cell to cancer. 
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